Alterations of intestinal epithelial barrier and flora in the irritable bowel syndrome;Anomalies pariétales et de la flore au cours du syndrome de l'intestin irritable

Gastroenterologie Clinique et Biologique

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Piche, T ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 5 RECEPTOR;

ARTICLE; BACTERIAL FLORA; ENTEROCHROMAFFIN CELL; HOST; HUMAN; INFECTION COMPLICATION; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MAST CELL; PATHOPHYSIOLOGY; CELL MEMBRANE PERMEABILITY; GASTROINTESTINAL MOTILITY; INTESTINE; INTESTINE MUCOSA; MICROBIOLOGY; PHYSIOLOGY;

CELL MEMBRANE PERMEABILITY; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL MOTILITY; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; IRRITABLE BOWEL SYNDROME;

EID: 62249185931     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(09)71524-6     Document Type: Article

References (57)

1. Piche T., Collins S.M., and Rampal P. Role of enteric infections and inflammation in functional bowel disorders. Gastroenterol Clin Biol 26 (2002) 624-629
2. Dainese R., Galliani E.A., De Lazzari F., Di Leo V., and Naccarato R. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 94 (1999) 1892-1897
3. Tibble J.A., Sigthorsson G., Foster R., Forgacs I., and Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123 (2002) 450-460
4. Lobley R.W., Burrows P.C., Warwick R., Dawson D.J., and Holmes R. Simultaneous assessment of intestinal permeability and lactose tolerance with orally administered raffinose, lactose and L-arabinose. Clin Sci (Lond) 79 (1990) 175-183
5. Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., and Collins S.M. Intestinal permeability in patients with irritable bowel syndrome after a waterbone outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Therap 20 (2004) 1317-1322
6. Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47 (2000) 804-811
7. Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 101 (2006) 1288-1294
8. Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 57 (2008) 591-599
9. Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome patients: involvement of soluble mediators. Gut 58 (2009) 196-201
10. Hiatt R., and Katz L. Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 37 (1962) 541-545
11. Salzmann J.L., Peltier-Koch F., Bloch F., Petite J.P., and Camilleri J.P. Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest 60 (1989) 847-851
12. Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122 (2002) 1778-1783
13. Talley N.J. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 98 (2003) 750-758
14. Dunlop S.P., Jenkins D., and Spiller R.C. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 98 (2003) 1578-1583
15. Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J., et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347 (1996) 150-153
16. Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3 (2005) 349-357
17. El-Salhy M., Danielsson A., Stenling R., and Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242 (1997) 413-419
18. Wheatcroft J., Wakelin D., Smith A., Mahoney C.R., Mawe G., and Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 17 (2005) 863-870
19. Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126 (2004) 1657-1664
20. Camilleri M., Andrews C.N., Bharucha A.E., Carlson P.J., Ferber I., Stephens D., et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132 (2007) 17-25
21. Tornblom H., Lindberg G., Nyberg B., and Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123 (2002) 1972-1979
22. Bishoff S.C., and Krämer S. Human mast cells, bacteria, and intestinal immunity. Immunological Reviews 219 (2007) 329-337
23. O'Sullivan M., Clayton N., Breslin N.P., Harman I., Bountra C., McLaren A., et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 12 (2000) 449-457
24. Piche T., Saint-Paul M.C., Dainese R., Marine-Barjoan E., Iannelli A., Montoya M.L., et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 57 (2008) 468-473
25. Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56 (2007) 203-209
26. Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126 (2004) 693-702
27. Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., et al. Mast cell-dependent excitation of visceralnociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132 (2007) 26-37
28. Roka R., Rosztoczy A., Leveque M., Izbeki F., Nagy F., Molnar T., et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 5 (2007) 550-555
29. Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117 (2007) 636-647
30. Akiho H., Deng Y., Blennerhassett P., Kanbayashi H., and Collins S.M. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 129 (2005) 131-141
31. McFarland L.V., and Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14 (2008) 2650-2661
32. Frissora C.L., and Cash B.D. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 25 (2007) 1271-1281
33. Chaudhary N.A., and Truelove S.C. The irritable bowel syndrome. Quart J Med 31 (1962) 307-322
34. McKendrick M.W., and Read N.W. Irritable bowel syndrome-post salmonella infection. J Infect 39 (1994) 1-3
35. Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 52 (2003) 523-526
36. Neal K.R., Hebden J., and Spiller J. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314 (1997) 779-782
37. Thornley J.P., Brough J., Wright T., Neal K.R., Jenkins D., and Spiller R.C. Bacterial toxins influence long term bowel dysfunction following campylobacter enteritis. Gastroenterology (2000)
38. Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., and Collins S.M. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 131 (2006) 445-450 quiz 660
39. Piche T., Vanbiervliet G., Pipau F.G., Dainese R., Hebuterne X., Rampal P., et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. Can J Gastroenterol 21 (2007) 727-731
40. Balsari A., Ceccarelli A., Dubini F., Fesce E., and Poli G. The fecal microbiota population in the irritable bowel syndrome. Microbiologica 5 (1982) 185-194
41. Si J.M., Yu Y.C., Fan Y.J., and Chen S.J. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10 (2004) 1802-1805
42. Mättö J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43 (2005) 213-222
43. Kassinen A., Krogius-Kurrikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133 (2007) 24-33
44. Furrie E., Macfarlane S., Thomson G., and Macfarlane G.T. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115 (2005) 565-574
45. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Giochetti P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
46. Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., and Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43 (2005) 3380-3389
47. King T.S., Elia M., and Hunter J.O. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352 (1998) 1187-1189
48. Salvioli B., Serra J., Azpiroz F., Lorenzo C., Aguade S., Castel J., et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology 128 (2005) 574-579
49. Pimentel M., Chow E., and Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms in irritable bowel syndrome. Am J Gastroenterol 95 (2000) 3503-3505
50. Pimentel M., Chow E., and Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double blind, randomized controlled study. Am J Gastroenterol 98 (2003) 412-419
51. Walters B., and Vanner S.J. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 100 (2005) 1566-1570
52. Esposito I., deLeone A., Di Gregorio G., Giaquinto S., deMagistris L., Ferrieri A., et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 13 (2007) 6016-6021
53. Grover M., Kanazawa M., Palsson O.S., Chitkara D.K., Gangarosa L.M., Drossman D.A., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 20 (2008) 998-1008
54. Madrid A.M., Defilippi C.C., Defilippi G.C., Slimming A.J., and Quera P.R. Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases. Rev Med Chil 135 (2007) 1245-1252
55. Majewski M., and McCallum R.W. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 52 (2007) 139-142
56. Sharara A.I., Aoun E., Abdul-Baki H., Mounzer R., Sidani S., and Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101 (2006) 326-333
57. Posserud I., Ersryd A., and Simren M. Functional findings in irritable bowel syndrome. World J Gastroenterol 12 (2006) 2830-2838